Impact on Life Expectancy of Withdrawing Thiopurines in Patients with Crohn’s Disease in Sustained Clinical Remission: A Lifetime Risk-Benefit Analysis [PDF]
PLoS ONE, 2016 Berenice Study GroupInternational audienceObjectiveLong-term treatment with thiopurines is associated with a decreased risk of Crohn’s disease (CD) flare but an increased risk of various cancers depending on gender, age, and presence of extensive colitis.
BERENICE Study Group +6 more
core +13 more sources
Thiopurine S -methyltransferase polymorphisms: efficient screening method for patients considering taking thiopurine drugs [PDF]
European Journal of Clinical Pharmacology, 2018 Objective: More than 11% of the Caucasian population are heterozygous or homozygous carriers of thiopurine S-methyltransferase (TPMT) mutants and are at risk for toxic side effects when treated with thiopurine drugs.
Fried, M. +5 more
core +4 more sources
Cytotoxicity of Thiopurine Drugs in Patients with Inflammatory Bowel Disease
Toxics, 2022 The effectiveness of thiopurine drugs in inflammatory bowel disease (IBD) was confirmed more than a half-century ago. It was proven that these can be essential immunomodulatory medications.
Oliwia Zakerska-Banaszak +5 more
doaj +1 more source
NUDT15 Pharmacogenetics in Acute Lymphoblastic Leukemia: Synthesizing Progress for Personalized Thiopurine Therapy. [PDF]
Med Sci (Basel)The management of acute lymphoblastic leukemia (ALL), the most common pediatric malignancy, critically relies on thiopurine therapy, such as 6-mercaptopurine (6-MP), during the maintenance phase. However, significant inter-individual response variety and
Lubis IS +5 more
europepmc +2 more sources
Pharmacogenetics and Genomics, 2010 The thiopurine drugs are purine antimetabolites widely used in the treatment of acute lymphoblastic leukemia, autoimmune disorders (e.g. Crohn’s disease and rheumatoid arthritis) and of organ transplant recipients. As inactive prodrugs, 6-mercaptopurine (6-MP), 6-thioguanine (6-TG) and azathioprine require intracellular activation, catalyzed by ...
Gianluigi Zaza +11 more
openaire +7 more sources
Pharmacogenomic tests in Oncology - finding the right dose
Brazilian Journal of Oncology, 2021 A pharmacogenetics/genomics (PGx) anticancer drug testing program is being developed by Kurtz and his group at the Brazilian National Cancer Institute (INCA).
Jeziel Basso, Gilberto Schwartsmann
doaj +1 more source
Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and/or thiopurine therapy: a multicenter study from Japan [PDF]
Intestinal Research, 2016 Background/AimsAnti-tumor necrosis factor drugs (anti-TNF) and thiopurines are important treatment options in patients with inflammatory bowel disease (IBD), including during pregnancy.
Shunsuke Komoto +15 more
doaj +1 more source
Frontiers in Nutrition, 2023 IntroductionThiopurines, azathiopurine (AZA) and mercaptopurine (6-MP) have been regularly used in the treatment of inflammatory bowel disease (IBD). Despite optimized dosage adjustment based on the NUDT15 genotypes, some patients still discontinue or ...
Pan Li +15 more
doaj +1 more source
Pharmacotherapy of inflammatory bowel diseases: efficacy performance and safety management
Терапевтический архив, 2021 Treatment of inflammatory bowel diseases IBD (Crohns disease, ulcerative colitis) is aimed at achieving clinical, endoscopic and histological remission, minimizing surgical complications, and ensuring a normal quality of life.
Igor G. Bakulin +10 more
doaj +1 more source
Systematic review and network meta-analysis comparing the efficacy of conventional therapy and biologics to prevent endoscopic postoperative recurrence in patients with Crohn's disease. [PDF]
Ther Adv GastroenterolBackground: As no direct comparison is available between drugs to prevent endoscopic postoperative recurrence (POR) in Crohn’s disease (CD), hierarchizing these therapeutic options remains challenging. Objectives: We aimed to compare the effectiveness of
Hupé M, Pereira B, Buisson A.
europepmc +2 more sources